Singapore: Sanofi and Regeneron Pharmaceuticals have received US Food and Drug Administration (FDA) approval for ZALTRAP...
Singapore: Exclusivity is everything in the pharmaceutical brand business. Without it, power over pricing disappears and...
Singapore: Eisai has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for its multi...
Singapore: Australia-based QRxPharma is proceeding with US FDA to discuss the company's Moxduo new drug application (NDA...
Singapore: Japan-headquartered Daiichi Sankyo has completed patient enrollment in the global Hokusai-VTE phase III study...
Singapore: Daiichi Sankyo and Amplimmune have entered into a strategic collaboration to develop a new therapeutic prote...
Singapore: The independent Data Monitoring Committee (DMC) of the phase III MARQUEE (Met inhibitor ARQ 197 plus Erlotin...
Singapore: Carrying a copy of a gene variant called ApoE4 confers a substantially greater risk for Alzheimer's disease o...
Singapore: US Food and Drug Administration (FDA) and the European Commission have granted orphan drug designation to Boe...
Singapore: Gilead's drug Sovaldi for hepatitis C virus, GlaxoSmithKline/Theravance's Anoro Ellipta for Chronic Obstructi...
Singapore: Johnson & Johnson has acquired Aragon Pharmaceuticals, a privately-held pharmaceutical discovery and deve...
Singapore: A new study published in Restorative Neurology and Neuroscience demonstrates that Chinese herbal medicine Ji-...
Singapore: University College London (UCL) and Japanese pharmaceutical company Eisai, have entered into a new agreement ...
Singapore: Novartis planning to leverage on its R&D pipeline to taste commercial success through 2017. Continuing R&...
Singapore: BRIM Biotechnology has collaborated with Janssen Pharmaceutica to pursue research, development and commercial...
Phylogica, a leading peptide drug discovery company based in Australia, has developed a world-class drug discovery platf...
Singapore: Japanese firm Ono Pharmaceutical and BioFocus, a service division of Galapagos and based in the UK, have sign...
Singapore: Specialty pharmaceutical company Hatchtech successfully completed end-of-phase II (EOP2) consultations with t...
